Lixte Biotechnology Holdings (FRA:8640) Scaled Net Operating Assets : -0.19 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Lixte Biotechnology Holdings's operating assets for the quarter that ended in Mar. 2025 was €0.12 Mil. Lixte Biotechnology Holdings's operating liabilities for the quarter that ended in Mar. 2025 was €0.33 Mil. Lixte Biotechnology Holdings's Total Assets for the quarter that ended in Dec. 2024 was €1.09 Mil. Therefore, Lixte Biotechnology Holdings's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2025 was -0.19.

Lixte Biotechnology Holdings Scaled Net Operating Assets Historical Data

The historical data trend for Lixte Biotechnology Holdings's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Scaled Net Operating Assets Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.02

-0.01

-0.04

-0.05

Lixte Biotechnology Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.07	-0.10	-0.10	-0.13	-0.19

Competitive Comparison of Lixte Biotechnology Holdings's Scaled Net Operating Assets

For the Biotechnology subindustry, Lixte Biotechnology Holdings's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Scaled Net Operating Assets falls into.

Save Embed

;

Save Embed

;

Lixte Biotechnology Holdings Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Lixte Biotechnology Holdings's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2024 )
=	(Operating Assets (A: Dec. 2024 )	-	Operating Liabilities (A: Dec. 2024 ))	/	Total Assets (A: Dec. 2023 )
=	(0.102	-	0.304)	/	3.951
=	-0.05

where

	Operating Assets		(A: Dec. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1.094	-	0.992
=	0.102

	Operating Liabilities		(A: Dec. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.304	-	0	-	0
=	0.304

Lixte Biotechnology Holdings's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2025 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2025 )
=	(Operating Assets (Q: Mar. 2025 )	-	Operating Liabilities (Q: Mar. 2025 ))	/	Total Assets (Q: Dec. 2024 )
=	(0.119	-	0.328)	/	1.094
=	-0.19

where

	Operating Assets		(Q: Mar. 2025 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1.4	-	1.281
=	0.119

	Operating Liabilities		(Q: Mar. 2025 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.328	-	0	-	0
=	0.328

Lixte Biotechnology Holdings Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings Headlines

No Headlines